Login to Your Account

Pharma: Clinic Roundup

Friday, August 23, 2013
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said favorable results from two Phase III studies, Gemini I and Gemini II, evaluating the humanized monoclonal antibody vedolizumab for moderately to severely active ulcerative colitis and Crohn's disease were published in the Aug. 22, 2013, issue of the New England Journal of Medicine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription